The ability of the growth factors epidermal growth factor (EGF), transforming growth factor ␣, and platelet-derived growth factor to exert insulin-like effects on glucose transport and lipolysis were examined in human and rat fat cells. No effects were found in rat fat cells, whereas EGF (EC 50 for glucose transport ϳ0.02 nM) and transforming growth factor ␣ (EC 50 ϳ0.2 nM), but not platelet-derived growth factor, mimicked the effects of insulin (EC 50 ϳ0.2 nM) on both pathways. EGF receptors, but not EGF, were abundantly expressed in human fat cells as well as in human skeletal muscle. EGF increased the tyrosine phosphorylation of several proteins (the EGF receptor, insulin receptor substrate (IRS)-1, IRS-2, and Grb2-associated binder 1), whereas Shc and Gab2 were only weakly and inconsistently phosphorylated. p85, the regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase), was also found to associate with all of these docking molecules, showing that EGF activated PI 3-kinase pools that were additional to those of insulin. EGF and/or insulin increased protein kinase B/Akt serine phosphorylation to a similar extent, whereas mitogen-activated protein kinase phosphorylation was more pronounced for EGF than for insulin. The impaired insulin-stimulated downstream signaling, measured as protein kinase B/Akt serine phosphorylation, in insulinresistant cells (Type 2 diabetes) was improved by the addition of EGF. Thus, EGF receptors, but not EGF, are abundantly expressed in human fat cells and skeletal muscle. EGF mimics the effects of insulin on both the metabolic and mitogenic pathways but utilize in part different signaling pathways. Both insulin and EGF increase the tyrosine phosphorylation and activation of IRS-1 and IRS-2, whereas EGF is also capable of activating additional PI 3-kinase pools and, thus, can augment the downstream signaling of insulin in insulin-resistant states like Type 2 diabetes.The insulin receptor belongs to a large family of receptor tyrosine kinases, also including receptors for epidermal growth factor (EGF), 1 platelet-derived growth factor (PDGF), hepatocyte growth factor, and fibroblast growth factor (1, 2).Binding of the ligand to the cognate growth receptors initiates a complex network of intracellular signals leading to cell growth, differentiation, and transformation (1, 2). However, growth factors do usually not initiate the various metabolic effects seen with insulin, such as increased glucose transport and GLUT4 translocation (3).Following insulin binding, the insulin receptor undergoes autophosphorylation, and this event allows the propagation of signals by phosphorylation on tyrosine and, subsequently, on serine residues of several downstream signaling molecules. The insulin receptor substrates (IRSs), particularly IRS-1, are the main docking proteins in the insulin signaling pathway. They have several sites that, upon tyrosine phosphorylation, bind proteins with Src homology 2/3 (SH2/SH3) domains or adaptor proteins like the 85-kDa regulatory subunit of PI 3-kinase, ...